Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

World Syndromic Multiplex Diagnostic Markets, 2024-2029: How Syndromic Molecular Diagnostics is Replacing Traditional Panel-based Ordering of Infectious Disease Tests

DUBLIN, Feb. 23, 2024 /PRNewswire/ -- The "Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts. Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI Etc.), by Country, with Market Analysis, Executive Guides and Customization" report has been added to  ResearchAndMarkets.com's offering.


The report includes five year market forecasts. In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.

The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. 

Key Topics Covered:

1 Market Guides
1.1 Situation Analysis & COVID Impact Overview
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants
1.4 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition
2.1 What are Syndromic Multiplex Tests?
2.2 Syndromic Testing - the quiet revolution in diagnostics
2.3 Market Definition
2.4 Methodology
2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic

3 The Infectious Diseases - Guide to the Pathogens
3.1 The Coronavirus
3.2 Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)
3.3 HIV - Human Immunodeficiency Virus (AIDS)
3.4 HBV - Hepatitis B
3.5 HCV - Hepatitis C
3.6 HPV - Human papillomavirus
3.7 Influenza
3.8 CTGC - Chlamydia/Gonorrhea
3.9 Tuberculosis
3.10 MRSA - Methicillin-resistant Staphylococcus aureus
3.11 VRE - Vancomycin-resistant Enterococcus

4 Industry Overview
4.1 Industry Participants
4.2 The Clinical Laboratory Market Segments
4.3 Industry Structure

5 Market Trends
5.1 Factors Driving Growth
5.1.1 Speed of Diagnosis.
5.1.2 Effect of Syndromic Testing on Costs.
5.1.3 Point of Care Advantage.
5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
5.1.5 Single Visits.
5.1.6 Improvement in Outcomes.
5.1.7 Impact of the COVID-19 Pandemic.
5.2 Factors Limiting Growth
5.2.1 Lower Prices.
5.2.2 Administration/reimbursement.
5.2.3 Infectious Disease is Declining But..
5.2.4 Wellness Hurts.
5.2.5 Economic Growth improves Living Standards.
5.2.6 Impact of the Pandemic Recession
5.3 Instrumentation and Automation
5.3.1 Instruments Key to Market Share
5.3.2 The Shrinking Machine.
5.3.3 Syndrome Testing Moving to Big Instruments?
5.4 Diagnostic Technology Development
5.4.1 Syndromictrends.com
5.4.2 Comparing Syndrome and Targeted Testing
5.4.3 The Multiplex Paradigm Shift
5.4.4 The Sepsis Testing Market - Bellwether for Syndromics
5.4.5 The Single Visit and Anti-Microbial Resistance
5.4.6 Syndromics drives POCT adoption.
5.4.7 A Big Future for PCR?

6 Syndromic Testing Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 QuantuMDx Developing Syndromic Panels for European Launch
6.3 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
6.4 QuantumDx Gets CE Mark for Rapid PoC PCR System
6.5 Bio-Rad Laboratories, Seegene Partner for MDx Development
6.6 Baebies to Expand Finder Platform
6.7 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
6.8 Binx Health Targeting Clinics, DTC & OTC With STI Tests
6.9 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
6.10 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
6.11 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
6.12 New Approach Involves Silicon-Based Test for Infectious Disease Screening
6.13 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
6.14 Qiagen sees NeuMoDx as Growth Vehicle
6.15 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
6.16 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
6.17 BioMerieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
6.18 Infectious Disease Testing Firm Curative Acquires KorvaLabs
6.19 ChromaCode Raises Additional $10M
6.20 COVID-19 Patients Need Syndromic Testing
6.21 GenMark Diagnostics - New Respiratory Panel due in June
6.22 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
6.23 Exact Diagnostics launches respiratory panel control
6.24 bioMerieux submits enhanced BIOFIRE BCID2 Panel to FDA
6.25 Nanomix Receives CE Mark for Diagnostic
6.26 Applied BioCode Applies to FDA for Syndromic Respiratory Panel
6.27 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
6.28 QIAGEN's New GI Panel Performance Assessed
6.29 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
6.30 Applied BioCode Obtains FDA Clearance
6.31 Meridian Bioscience to Acquire GenePOC Inc.
6.32 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
6.33 Qiagen gets FDA clearance for syndromic testing system
6.34 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMerieux
6.35 Akonni Biosystems Submits Multiplex Diagnostics System to FDA
6.36 Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
6.37 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
6.38 QuantuMDx and Molbio announce MoU
6.39 Immunexpress Wins $745K Contract for Rapid Sepsis Assay
6.40 Mobidiag Inks European, Middle Eastern Distribution Deals
6.41 BIOFIRE FILMARRAY System chosen for Phase 3 clinical trial

7 Profiles of Key Syndromic Testing Companies
7.1 Abacus Diagnostica
7.2 Abbott Diagnostics
7.3 Accelerate Diagnostics
7.4 Ador Diagnostics
7.5 Akonni Biosystems
7.6 Alveo Technologies
7.7 Antelope Dx
7.8 Applied BioCode
7.9 Aus Diagnostics
7.10 Baebies
7.11 Beckman Coulter Diagnostics
7.12 Becton, Dickinson and Company
7.13 Binx Health
7.14 Biocartis
7.15 BioFire Diagnostics (bioMerieux)
7.16 bioMerieux Diagnostics
7.17 Bio-Rad Laboratories, Inc
7.18 Bosch Healthcare Solutions GmbH
7.19 Cepheid (Danaher)
7.20 Credo Diagnostics Biomedical
7.21 Cue Health
7.22 Curetis N.V. / Curetis GmbH
7.23 Diagenode Diagnostics
7.24 Diasorin S.p.A.
7.25 Enzo Life Sciences, Inc.
7.26 Eurofins Scientific
7.27 Fluxergy
7.28 Fusion Genomics.
7.29 Genetic Signatures
7.30 GenMark Dx (Roche)
7.31 Hibergene Diagnostics
7.32 Hologic
7.33 Immunexpress
7.34 Inflammatix
7.35 Invetech
7.36 Janssen Diagnostics
7.37 Karius
7.38 Lexagene
7.39 LightDeck Diagnostics
7.40 Lucira Health
7.41 Luminex Corp
7.42 Maxim Biomedical
7.43 Meridian Bioscience
7.44 Mesa Biotech (Thermo Fisher)
7.45 Millipore Sigma
7.46 Mobidiag (Hologic)
7.47 Molbio Diagnostics
7.48 Nanomix
7.49 Novel Microdevices
7.50 Operon
7.51 Oxford Nanopore Technologies
7.52 Panagene
7.53 Perkin Elmer
7.54 Primerdesign (Novacyt)
7.55 Prominex
7.56 Qiagen Gmbh
7.57 Quantumdx
7.58 Quidel
7.59 Roche Molecular Diagnostics
7.60 Saw Diagnostics
7.61 Seegene
7.62 Siemens Healthineers
7.63 Sona Nanotech
7.64 SpeeDx
7.65 T2 Biosystems
7.66 Talis Biomedical
7.67 Thermo Fisher Scientific Inc.
7.68 Veramarx
7.69 Visby Medical
7.70 XCR Diagnostics

8 The Global Market for Syndromic Multiplex Diagnostics
8.1 Global Market Overview by Country
8.2 Global Market by Syndrome - Overview
8.3 Global Market by Place - Overview
8.4 Global Market by Product - Overview

9 Global Syndromic Multiplex Markets - By Syndrome
9.1 Respiratory
9.2 Gastrointestinal
9.3 Blood
9.4 Meningitis/Encephalitis
9.5 Sexually Transmitted Disease

10 Global MDx Infectious Disease Markets - by Place
10.1 Hospital Lab
10.2 Outpatient Lab
10.3 Point of Care

11 Global MDx Infectious Disease Markets - by Product
11.1 Instruments
11.2 Cartridges
11.3 Reagents

12 Appendices
12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

For more information about this report visit https://www.researchandmarkets.com/r/udio6b

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

These press releases may also interest you

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

18 avr 2024
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...

News published on and distributed by: